Phosphatase enzyme

Phosphatase enzymes are a large and diverse family of enzymes classified as hydrolases, specialized in catalyzing the removal of phosphate groups (dephosphorylation) from proteins, lipids, nucleotides, and carbohydrates[1][5]. They act as crucial regulators in signaling pathways, metabolic processes, cell cycle progression, and gene expression by reversing phosphorylation mediated by kinases[5][7]. There are several major classes based on substrate specificity and sequence homology, including protein phosphatases, lipid phosphatases, carbohydrate phosphatases, and nucleotidases[5][2]. The principal subclasses of protein phosphatases are protein serine/threonine phosphatases (PPP, PPM families) and protein tyrosine phosphatases (PTP family), each with many members involved in vital cellular processes and disease pathogenesis[2][3][8]. Phosphatases are considered significant therapeutic targets in diseases such as cancer, neurodegeneration, and immune disorders, but broad targeting and lack of high specificity have presented major drug development challenges[7][8]. “Phosphatase enzymes” is an overly broad category—commonly, more specific names should be used (e.g., Protein phosphatase 1, Calcineurin/PP2B, Protein tyrosine phosphatase 1B) rather than the generic plural form. Limitations/caveats: "Phosphatase enzymes" is too broad for a canonical drug target; more precise identification (e.g., naming a specific gene/protein) is needed for structured data and drug development[1][3]. Individual phosphatases may have unique aliases, interacting drugs, safety concerns, and disease roles. Information above is synthesized for the class, not any single molecule, as no specific phosphatase was identified in the query.

Other names

PhosphataseProtein phosphataseLipid phosphataseCarbohydrate phosphataseNucleotidaseAcid phosphataseAlkaline phosphataseSeveral specific names for subclasses (e.g., PP1, PP2A, PP2B/calcineurin, PTP1B, PTEN, DUSP family)

Inhibition of dephosphorylation (by blocking phosphatase activity, resulting in maintained phosphorylation states); Modulation of cell signaling by altering protein phosphorylation status; Suppression of immune responses (e.g., calcineurin inhibitors suppress T cells)